Custom-Made vaccine trial aims to boost immune attack on aggressive breast cancer
NCT ID NCT06631092
Summary
This early-stage trial is testing a personalized vaccine called NECVAX-NEO1. It is given alongside standard chemotherapy and immunotherapy to patients with triple-negative breast cancer before surgery. The goal is to see if adding this custom-made vaccine, designed to target each patient's specific tumor, is safe and helps the body fight the cancer more effectively.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Center for Tumor Diseases Heidelberg
RECRUITINGHeidelberg, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Clinic Erlangen
RECRUITINGErlangen, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.